Crossmark

Cost-effectiveness of lurbinectedin with atezolizumab for extensive-stage small-cell lung cancer in the United States: impact of drug wastage reduction on economic outcomes

Crossref DOI link: https://doi.org/10.1186/s12913-026-14653-5

Published Online: 2026-05-04

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Zhu, Jiaming

Li, Zhengxiong

Song, Danlei

Liu, Wen
License Information

Text and Data Mining valid from 2026-05-04

Version of Record valid from 2026-06-16
More Information

Article History

Received: 15 September 2025

Accepted: 24 April 2026

First Online: 4 May 2026

Declarations

:

: As this study involved only secondary analyses of previously published and publicly available, de-identified data, it was exempt from review and approval by an ethics committee or institutional review board, either under the guidelines of the Ethics Committee of Zhejiang Chinese Medical University (China) or under the US Department of Health and Human Services regulations (45 C.F.R. § 46.104[d] [ ]). Informed consent to participate was not applicable. The study was conducted in accordance with the principles of the Declaration of Helsinki.

: Not applicable.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below